Teva Pharmaceutical Industries (TEVA) – Research Analysts’ Recent Ratings Updates

A number of firms have modified their ratings and price targets on shares of Teva Pharmaceutical Industries (NYSE: TEVA) recently:

• 11/5/2026 – Teva Pharmaceutical Industries had its price target raised by Leerink Partners from $45.00 to $52.00. They now have an “outperform” rating on the stock.
• 11/4/2026 – Teva Pharmaceutical Industries was upgraded by Weiss Ratings from “hold (c)” to “hold (c+)”.
• 11/4/2026 – Teva Pharmaceutical Industries had its price target raised by TD Cowen from $55.00 to $57.00. They now have a “buy” rating on the stock.
• 11/2/2026 – Teva Pharmaceutical Industries is now covered by HC Wainwright. They set a “buy” rating and a $52.00 price target on the stock.
• 10/20/2026 – Teva Pharmaceutical Industries was downgraded by Zacks Research from “hold” to “strong sell”.
• 10/15/2026 – Teva Pharmaceutical Industries had its price target raised by Barclays from $42.00 to $47.00. They now have an “overweight” rating on the stock.
• 10/12/2026 – Teva Pharmaceutical Industries had its price target raised by JPMorgan Chase & Co. from $40.00 to $50.00. They now have an “overweight” rating on the stock.
• 10/9/2026 – Teva Pharmaceutical Industries had its price target raised by Oppenheimer from $50.00 to $52.00. They now have an “outperform” rating on the stock.
• 10/8/2026 – Teva Pharmaceutical Industries was upgraded by Weiss Ratings from “hold (c-)” to “hold (c)”.
• 10/1/2026 – Teva Pharmaceutical Industries is now covered by TD Cowen. They set a “buy” rating and a $55.00 price target on the stock.
• 9/23/2026 – Teva Pharmaceutical Industries is now covered by Oppenheimer. They set an “outperform” rating and a $50.00 price target on the stock.

Teva Pharmaceutical Industries Stock Performance

Shares of NYSE:TEVA opened at $42.41 on Wednesday. The company has a 50-day moving average price of $39.75 and a 200-day moving average price of $34.90. The company has a market cap of $49.41 billion, a price-to-earnings ratio of 98.62, a price-to-earnings-growth ratio of 4.04 and a beta of 0.97. The company has a current ratio of 0.95, a quick ratio of 0.74 and a debt-to-equity ratio of 1.59. Teva Pharmaceutical Industries Ltd. has a 12 month low of $24.01 and a 12 month high of $43.34.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Tuesday, November 3rd. The company reported $0.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.14. The firm had revenue of $4.39 billion for the quarter, compared to analysts’ expectations of $4.23 billion. Teva Pharmaceutical Industries had a return on equity of 33.20% and a net margin of 2.94%. The business’s revenue was down 1.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.78 earnings per share. As a group, equities analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 1.97 EPS for the current year.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, insider Brian Savage sold 7,342 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Friday, September 18th. The stock was sold at an average price of $38.85, for a total transaction of $285,236.70. Following the sale, the insider directly owned 8,500 shares of the company’s stock, valued at approximately $330,225. The trade was a 46.35% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Mark Sabag sold 46,000 shares of the stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $41.93, for a total value of $1,928,780.00. Following the completion of the transaction, the insider directly owned 80,760 shares of the company’s stock, valued at $3,386,266.80. This represents a 36.29% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 420,942 shares of company stock worth $16,572,473 over the last three months. Company insiders own 0.54% of the company’s stock.

Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures and markets generic medicines, specialty medicines and biosimilars. Its portfolio spans treatments for conditions including neurological disorders, respiratory diseases and cancer, alongside a broad range of generic medicines across therapeutic areas. Founded in Jerusalem in 1901, Teva has grown from a regional pharmaceutical business into an international company. It serves patients and healthcare providers in markets around the world, including North America, Europe and other regions.